These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8024227)

  • 1. [Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent].
    Titon JP; Auger D; Grange P; Hecquet JP; Remond A; Ulliac P; Vaissié JJ
    Ann Cardiol Angeiol (Paris); 1994 Mar; 43(3):160-6. PubMed ID: 8024227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance].
    Forette B; Wolmark Y
    Presse Med; 1995 Mar; 24(12):567-71. PubMed ID: 7770402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium).
    Haentjens P
    Injury; 1996 Jul; 27(6):385-90. PubMed ID: 8881132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
    Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
    Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
    Kalfarentzos F; Stavropoulou F; Yarmenitis S; Kehagias I; Karamesini M; Dimitrakopoulos A; Maniati A
    Obes Surg; 2001 Dec; 11(6):670-6. PubMed ID: 11775562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and tolerability of fraxiparine in the prevention of thromboembolic complications in oncologic thoracic surgery].
    Azorin JF; Regnard JF; Dahan M; Pansart M
    Ann Cardiol Angeiol (Paris); 1997; 46(5-6):341-7. PubMed ID: 9295896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis.
    Uncu H
    Phlebology; 2009 Apr; 24(2):56-60. PubMed ID: 19299272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients.
    Egger B; Schmid SW; Naef M; Wildi S; Büchler MW
    Dig Surg; 2000; 17(6):602-609. PubMed ID: 11155006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
    Mismetti P; Mille D; Laporte S; Charlet V; Buchmüller-Cordier A; Jacquin JP; Fournel P; Dutrey-Dupagne C; Decousus H;
    Haematologica; 2003 Jan; 88(1):67-73. PubMed ID: 12551829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
    Agnelli G; Gussoni G; Bianchini C; Verso M; Mandalà M; Cavanna L; Barni S; Labianca R; Buzzi F; Scambia G; Passalacqua R; Ricci S; Gasparini G; Lorusso V; Bonizzoni E; Tonato M;
    Lancet Oncol; 2009 Oct; 10(10):943-9. PubMed ID: 19726226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H; Marchetti O; Haeberli A; Mombelli G
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
    Lévesque H; Cailleux N; Vasse D; Legallicier B; Moore N; Borg JY; Hantute N; Thuillez C; Courtois H
    Therapie; 1994; 49(2):101-5. PubMed ID: 7817331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.
    Barradell LB; Buckley MM
    Drugs; 1992 Nov; 44(5):858-88. PubMed ID: 1280570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
    Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.
    Fraisse F; Holzapfel L; Couland JM; Simonneau G; Bedock B; Feissel M; Herbecq P; Pordes R; Poussel JF; Roux L
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1109-14. PubMed ID: 10764298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The home treatment of deep venous thromboses with low-molecular-weight heparin].
    Grau Segura E; Real Vila E; Pastor Guzmán E; Torró Richart JA; Garay Burdeos M
    Rev Clin Esp; 1997 Jun; 197(6):398-401. PubMed ID: 9304129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.